P2X7 receptor involved in antitumor activity of atractylenolide I in human cervical cancer cells

• Published in: Purinergic signalling Vol. 19; no. 1; pp. 145 - 153
• Main Authors: Han, Yue, Bai, Can, He, Xi-Meng, Ren, Qing-Ling
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.03.2023; Springer Nature B.V
• Subjects: Agonists; Antineoplastic Agents - therapeutic use; Antitumor activity; Biomedical and Life Sciences; Biomedicine; Cancer Research; Cell Proliferation; Cervical cancer; Female; HeLa Cells; Human papillomavirus; Human Physiology; Humans; Neurosciences; Original; Original Article; Pharmacology/Toxicology; Purinergic P2X Receptor Antagonists - pharmacology; Receptors, Purinergic P2X7; Uterine Cervical Neoplasms; Human cervical cancer cells; Atractylenolide I; Hela cells; P2X7Rs; SiHa cells
• ISSN: 1573-9538; 1573-9546
• DOI: 10.1007/s11302-022-09854-6

Atractylenolide I (Atr-I) was found to sensitize a variety of human cancer cells in previous studies. Purinergic P2X7R plays important role in different cancers. However, whether Atr-I could generate antitumor activity in human cervical cancer cells and P2X7R get involved in this effect remain unclear. In this study, Hela (HPV 18 +) and SiHa (HPV 16 +) cells were treated with different doses of Atr-I. The results indicated that agonist and antagonist of P2X7 receptors, BzATP and JNJ-47965567 (JNJ), could suppress the proliferation of Hela and SiHa cells. Atr-I demonstrated a considerable antitumor effect in both human cervical cancer cells in vitro. Atr-I combined with P2X7R agonist, BzATP, restored Atr-I-induced growth inhibition in Hela cells but not in SiHa cells. However, the combinatorial treatment of P2X7R antagonist JNJ and Atr-I has an additive effect on cell growth inhibition in SiHa cells rather than in Hela cells. It implied that P2X7R would get involved in the anti-human cervical cancer cells effect of Atr-I.